Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H6N4S |
| Molecular Weight | 166.204 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CSC1=C2NC=NC2=NC=N1
InChI
InChIKey=UIJIQXGRFSPYQW-UHFFFAOYSA-N
InChI=1S/C6H6N4S/c1-11-6-4-5(8-2-7-4)9-3-10-6/h2-3H,1H3,(H,7,8,9,10)
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Purine analogs as potential anticytomegalovirus agents. | 1969 Sep |
|
| Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. | 2001 Aug 1 |
|
| Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography: comparison with the radiochemical method. | 2001 Oct |
|
| Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. | 2003 May-Jun |
|
| Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. | 2004 Aug |
|
| Improved HPLC methodology for monitoring thiopurine metabolites in patients on thiopurine therapy. | 2004 Sep |
|
| Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. | 2005 Aug |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
| [HPLC determination and diversity analysis of thiopurine methyltransferase activity in human and pig]. | 2006 May |
|
| Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. | 2006 Oct |
|
| Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center. | 2006 Sep |
|
| Molecular mechanisms underlying the enhanced sensitivity of thiopurine-resistant T-lymphoblastic cell lines to methyl mercaptopurineriboside. | 2006 Sep 28 |
|
| Optimizing drug therapy in inflammatory bowel disease. | 2007 Dec |
|
| 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. | 2007 Jul |
|
| Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. | 2008 Dec |
|
| Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. | 2008 Dec |
|
| Stability of thiopurine metabolites: a potential analytical bias. | 2008 Jan |
|
| [Optimising azathioprine treatment: determination of thiopurine methyltransferase activity and thiopurine metabolites]. | 2009 Feb |
|
| Patent watch. Drug metabolite claims are patentable. | 2009 Nov |
|
| Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease. | 2010 Dec |
|
| Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. | 2010 Feb |
|
| Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases. | 2010 Jul-Sep |
|
| How should thiopurine treatment be monitored?--methodological aspects. | 2010 Jun |
|
| Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practise. | 2010 Jun 1 |
|
| A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. | 2010 Nov |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5778
Created by
admin on Fri Dec 15 17:05:54 GMT 2023 , Edited by admin on Fri Dec 15 17:05:54 GMT 2023
|
PRIMARY | |||
|
28279
Created by
admin on Fri Dec 15 17:05:54 GMT 2023 , Edited by admin on Fri Dec 15 17:05:54 GMT 2023
|
PRIMARY | |||
|
6V404DV25O
Created by
admin on Fri Dec 15 17:05:54 GMT 2023 , Edited by admin on Fri Dec 15 17:05:54 GMT 2023
|
PRIMARY | |||
|
SUB181031
Created by
admin on Fri Dec 15 17:05:54 GMT 2023 , Edited by admin on Fri Dec 15 17:05:54 GMT 2023
|
PRIMARY | |||
|
200-057-3
Created by
admin on Fri Dec 15 17:05:54 GMT 2023 , Edited by admin on Fri Dec 15 17:05:54 GMT 2023
|
PRIMARY | |||
|
100000166797
Created by
admin on Fri Dec 15 17:05:54 GMT 2023 , Edited by admin on Fri Dec 15 17:05:54 GMT 2023
|
PRIMARY | |||
|
20105
Created by
admin on Fri Dec 15 17:05:54 GMT 2023 , Edited by admin on Fri Dec 15 17:05:54 GMT 2023
|
PRIMARY | |||
|
DTXSID50901654
Created by
admin on Fri Dec 15 17:05:54 GMT 2023 , Edited by admin on Fri Dec 15 17:05:54 GMT 2023
|
PRIMARY | |||
|
50-66-8
Created by
admin on Fri Dec 15 17:05:54 GMT 2023 , Edited by admin on Fri Dec 15 17:05:54 GMT 2023
|
PRIMARY |
PARENT (METABOLITE INACTIVE)
SUBSTANCE RECORD
